|Bid||54.87 x 100|
|Ask||55.28 x 500|
|Day's Range||55.92 - 56.99|
|52 Week Range||53.36 - 66.80|
|PE Ratio (TTM)||60.53|
|Earnings Date||May 1, 2018|
|Forward Dividend & Yield||1.92 (3.41%)|
|1y Target Est||66.67|
A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. Gilead in a statement on Saturday said it always believed the patent was invalid and was pleased the judge confirmed that opinion.
The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. Gilead did not immediately respond to a request for comment on Saturday. The December 2016 verdict followed a trial in which jurors found that Merck's patent on hepatitis C treatments, which it acquired in 2014 when it bought Idenix Pharmaceuticals, was valid.
Merck & Co Inc. (NYSE:MRK) delivered a less impressive 6.73% ROE over the past year, compared to the 10.62% return generated by its industry. Though MRK’s recent performance is underwhelming,Read More...
Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck & Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round. Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib — into clinical studies.
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. Medicines tested to treat Alzheimer's have had a dismal track record, and the Food and Drug Administration has recognized that goals for clinical trials need to evolve to assess drugs aimed at earlier-stage patients. In proposed new guidelines released on Thursday, the FDA appears open to trial goals that better match early patient populations, including people who have yet to display memory loss or functional impairment, such as the ability to wash or dress themselves or cook meals.
Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies. In the late stage trial of Bavencio, the drug could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.
In fiscal 2017, Pfizer’s (PFE) Medrol generated revenues of $483 million, which was ~7% higher on a YoY (year-over-year) basis. In 2017, in the US and in international markets, Medrol reported revenues of $317 million and $167 million, respectively, which was ~11% and ~1% higher on a YoY basis. In 4Q17, Medrol reported revenues of $131 million, which represents a ~10% YoY rise and a 20% quarter-over-quarter rise.
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The ...
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Team, ...
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...